About 400 units.
In many clinical stories, ECMO, however, puts the patient's family in a dilemma, emotionally giving hope and financially devastating; more binding is that the emergency life-saving ECMO, the national stock is only about 400 or so (not counting Hong Kong, Macao, and Taiwan), and support for Hubei relies on the coordinated support of the whole country.
As of December 31, 2018, China*** had 260 hospitals with extracorporeal life-support centers carrying out ECMO treatments,*** counting about 400 ECMO devices, and even in the United States, where medical technology is extremely developed, the number of hospitals offering ECMO in 2019 is only 264, which is comparable to China.
Detailed introduction:
ECMO, also known as extracorporeal membrane oxygenation therapy device, referred to as "Yekke Membrane", and many doctors also refer to it as an "artificial heart-lung machine", its work The principle is to drain venous blood from the body to the outside of the body, oxygenate it with a gas exchange device, and then pump it back into the body with a driving pump, so that the heart and lungs can have a full rest.
Support for pulmonary function can effectively improve hypoxemia, avoiding oxygen toxicity caused by long-term hyperoxia inhalation and airway damage caused by mechanical ventilation; for cardiac function can increase and maintain cardiac output, improve systemic circulatory perfusion, and ensure circulatory stabilization, thus gaining time for cardiopulmonary function recovery.
ECMO is currently the core support for severe cardiopulmonary failure, and is also known as the "last straw" for critically ill patients, which corresponds to the high cost of the treatment.